AO-176 is under clinical development by Arch Oncology and currently in Phase II for Refractory Multiple Myeloma. According to GlobalData, Phase II drugs for Refractory Multiple Myeloma have a 35% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AO-176’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AO-176 overview
AO-176 is under development for the treatment of B-cell lymphoma and advanced solid tumors including epithelial ovarian carcinoma, T-cell acute lymphoblastic leukemia (ALL), including primary peritoneal and fallopian tube carcinoma, triple negative breast cancer, squamous cell carcinoma of head and neck, endometrial carcinoma, castration resistant prostate cancer, non-small cell lung adenocarcinoma, papillary thyroid carcinoma, relapsed/refractory multiple myeloma, pleural or peritoneal malignant mesothelioma and gastroesophageal adenocarcinoma. It acts by targeting leukocyte surface antigen CD47.
Arch Oncology overview
Arch Oncology is a company that is focused on the discovery and development of new antibody therapeutics, with best-in-class potential, to treat patients living with cancer. The company is headquartered in Brisbane, California, the US.
For a complete picture of AO-176’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
